MétaCan
Menu
Back to cohort
Record W2897384304 · doi:10.1002/ehf2.12355

Post Hoc Analyses of SHIFT and PARADIGM-HF Highlight the Importance of Chronic Chagas' Cardiomyopathy <i>Comment on:</i> “Safety Profile and Efficacy of Ivabradine in Heart Failure Due to Chagas Heart Disease: A Post Hoc Analysis of the SHIFT Trial” by Bocchi <i>et al.</i>

2018· letter· en· W2897384304 on OpenAlexaff
Félix José Alvarez Ramires, Felipe Martínez, Efraín Gómez, Caroline Demacq, Claudio Gimpelewicz, Jean L. Rouleau, Scott D. Solomon, Karl Swedberg, Michael R. Zile, Milton Packer, John J.V. McMurray

Bibliographic record

VenueESC Heart Failure · 2018
Typeletter
Languageen
FieldMedicine
TopicTrypanosoma species research and implications
Canadian institutionsUniversité de MontréalMontreal Heart Institute
Fundersnot available
KeywordsIvabradineMedicineHeart failureSacubitrilInternal medicineEnalaprilCardiologyValsartanCardiomyopathySacubitril, ValsartanPost-hoc analysisHeart rateEjection fractionAngiotensin-converting enzymeBlood pressure

Abstract

fetched live from OpenAlex

We read with interest the report by Bocchi and colleagues of their post hoc analysis of the Systolic Heart failure treatment with the If inhibitor ivabradine Trial (SHIFT), examining the effect of study drug in the 38 patients with chronic chagasic cardiomyopathy (CCC).1 The authors reported that study drug lowered heart rate and improved New York Heart Association class. The sample size was too small to allow estimation of the effect of treatment on mortality or hospitalization. However, this analysis did suggest that patients with CCC experienced high event rates, despite excellent background therapy. We examined outcomes in patients with CCC in the Prospective comparison of Angiotensin Receptor Neprilysin Inhibitor with Angiotensin Converting Enzyme Inhibitor to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) and the Aliskiren trial to Minimize OutcomeS in Patients with Heart failure (ATMOSPHERE).2, 3 These trials included 195 CCC patients from among a total of 2552 recruited in Latin America. Despite being younger and having less co-morbidity, the CCC patients had higher hospitalization and mortality rates, compared with other aetiologies, despite similarly good treatment.4 We also conducted an exploratory post hoc analysis of the effect of sacubitril/valsartan (formerly known as LCZ696) in CCC patients in PARADIGM-HF. Of a total of 113 patients, 58 were randomized to sacubitril/valsartan and 55 to enalapril. The two treatment groups were similar in terms of demographics, co-morbidity, and heart failure (HF) severity. Patients with CCC treated with sacubitril/valsartan, as compared with enalapril, had a lower risk of experiencing cardiovascular death or HF hospitalization, the primary composite endpoint, and each of its components (Figure). The point estimate for risk reduction was comparable with or greater than that seen with the drug vs. enalapril in the entire study population. This analysis is underpowered and should be interpreted with caution. CCC is a major health issue in Latin America and is now recognized in the USA and Europe, reflecting contemporary migration patterns.5-8 Indeed, a recent study from Brazil concluded that the population attributable mortality risk from CCC increased between 2002/2004 and 2012/2014.9 Future trials should consider recruiting larger numbers of patients with CCC to allow adequately powered subgroup analysis and even trials specifically in CCC would be justified, given the magnitude of this problem. Until that time, patients with CCC should be treated empirically with therapies recommended by guidelines, on the assumption that treatments for patients with reduced ejection fraction are effective, irrespective of aetiology of HF.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.102
metaresearch head score (Gemma)0.233
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.102
Threshold uncertainty score0.538

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.1020.233
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0040.010
Bibliometrics0.0010.002
Science and technology studies0.0010.004
Scholarly communication0.0020.004
Open science0.0040.001
Research integrity0.0060.012
Insufficient payload (model declined to judge)0.0090.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.014
GPT teacher head0.301
Teacher spread0.287 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations25
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueESC Heart FailureSame topicTrypanosoma species research and implicationsFrench-language works237,207